Abstracts tagged "etanercept"

Abstract Number: 1392 • 2018 ACR/ARHP Annual Meeting
Decreased Injection Site Pain Associated with New Etanercept Formulation in Patients with Rheumatoid Arthritis or Psoriatic Arthritis
Stanley Cohen¹, Ahmed Samad², Elaine Karis², Bradley S. Stolshek², Mona Trivedi², Hao Zhang², Girish A. Aras², Greg Kricorian² and James Chung², ¹Metroplex Clinical Research Center, Dallas, TX, ²Amgen Inc., Thousand Oaks, CA
Background/Purpose: Injection site pain (ISP) is a component of the patient experience with injectable drugs. A new formulation of etanercept was developed to reduce ISP.…
Abstract Number: 1553 • 2018 ACR/ARHP Annual Meeting
An Analysis of Real-World Data on the Safety of Etanercept in Elderly Patients with Rheumatoid Arthritis
Christopher J. Edwards¹, Jack F Bukowski², Sara Burns³, Heather Jones², Ronald Pedersen², Katherine Roshak², Joan M Sopczynski², Mazhar Thakur⁴ and Lisa Marshall², ¹University of Southampton, Southampton, United Kingdom, ²Pfizer, Collegeville, PA, ³Pfizer, Cambridge, MA, ⁴RegSafe Consulting Ltd, Wokingham, United Kingdom
Background/Purpose: Both rheumatoid arthritis (RA) and older age are associated with a higher risk of comorbidities, and the appropriate treatment approach for older patients is…
Abstract Number: 1986 • 2018 ACR/ARHP Annual Meeting
Adalimumab:TNF Complexes Are Cleared More Efficiently By Human Osteoclasts Than Those with Etanercept through Fcg-Receptor Binding and Internalization
Bohdan P. Harvey, Joel Cohen-Solal and Zehra Kaymakcalan, Biologics, AbbVie Bioresearch Center, Worcester, MA
Background/Purpose: TNF-alpha (TNFa) has been shown to contribute to osteoclastogenesis (OCgenesis) independently and in conjunction with M-CSF or RANKL, two key cytokines involved in osteoclast…
Abstract Number: 2383 • 2018 ACR/ARHP Annual Meeting
Pharmacovigilance of Biologics for Non-Systemic Juvenile Idiopathic Arthritis By the German Biologics Registry
Gerd Horneff¹, Gerd Ganser², Ivan Foeldvari³, Frank Weller-Heinemann⁴, Kirsten Minden⁵ and Ariane Klein⁶, ¹Asklepios Klinik Zentrum für Allgemeine Paediatrie und Neonatologie, Sankt Augustin, Germany, ²Klinik für Kinder-und Jugendrheumatologie, Nordwestdeutsches Rheumazentrum, Sendenhorst, Germany, ³Hamburg Centre for Pediatric Rheumatology, Hamburg, Germany, ⁴Prof.-Hess-Kinderklinik, Bremen,, Berlin, Germany, ⁵Charité–Universitätsmedizin Berlin, Berlin, Germany, ⁶Center of Pediatrics and Neonatology, Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany
Background/Purpose: Long-term surveillance of biologics is particularly important in pediatric patients (pts) who may require prolonged treatment. Since 2001, the German Biologics JIA Registry (BIKER)…
Abstract Number: 2395 • 2018 ACR/ARHP Annual Meeting
Tumor Necrosis Factor-α Inhibitor (TNFi)-Induced Psoriasis: Prevalence and Response to Therapy in Patients with Juvenile Idiopathic Arthritis (JIA) in Two Children’s Hospitals
Daniel Groth¹, Maria Perez², Simona Nativ³, James R. Treat⁴, Leslie Castelo-Soccio⁴, Pamela F. Weiss⁵, Marissa J. Perman⁴ and Sivia Lapidus³, ¹Pediatrics, Goryeb Children's Hospital, Morristown, NJ, ²Pediatric Gastroenterology, Goryeb Children's Hospital, Morristown, NJ, ³Pediatric Rheumatology, Goryeb Children's Hospital, Morristown, NJ, ⁴Pediatrics, Section of Dermatology, Children's Hospital of Philadelphia, Philadelphia, PA, ⁵Division of Rheumatology, Center for Pediatric Clinical Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: The development of psoriasis while on TNFi is a paradoxical effect of agents that treat psoriasis and is described in larger cohorts inflammatory bowel…
Abstract Number: 2396 • 2018 ACR/ARHP Annual Meeting
Reduction in the Utilization of Prednisone and/or Methotrexate Following the Initiation of Etanercept in Pediatric Patients
Majed M M Khraishi¹, Brad Millson², John Woolcott³, Lisa Marshall⁴ and Heather Jones⁴, ¹Memorial University of Newfoundland, St John's, NF, Canada, ²IQVIA, Kanata, ON, Canada, ³Global Outcomes & Evidence, Pfizer, Collegeville, PA, ⁴Pfizer, Collegeville, PA
Background/Purpose: In Canada, the pediatric indications of etanercept (ETN) are active ankylosing spondylitis (AS), plaque psoriasis (PsO) and moderate to severely active juvenile idiopathic arthritis…
Abstract Number: 2407 • 2018 ACR/ARHP Annual Meeting
New Onset of Uveitis in Non-Methotrexate Group, Methotrexate Group and Etanercept Group in Juvenile Idiopathic Arthritis
Mikhail Kostik, Ekaterina Gaidar, Maria Likhacheva, Eugenia Isupova, Irina Chikova, Margarita Dubko, Vera Masalova, Tatiana Likhacheva, Ludmila Snegireva, Tatiana Kornishina, Olga Kalashnikova and Vyacheslav Chasnyk, Saint-Petersburg State Pediatric Medical University, Saint-Petersburg, Russian Federation
Background/Purpose: Uveitis is the most common extra-articular manifestation of juvenile idiopathic arthritis (JIA), often entirely asymptomatic but could be sight-threatening. The most often prescribed biologics…
Abstract Number: 2512 • 2018 ACR/ARHP Annual Meeting
Treatment Continuation on the Etanercept Original in Comparison with a Biosimilar
Lisa Baganz¹, Yvette Meißner¹, Perter Herzer², Jürgen Braun³, Anett Gräßler⁴, Anja Strangfeld⁵ and Angela Zink⁶, ¹Programme Area Epidemiology, German Rheumatism Research Center, Berlin, Germany, ²Scientific Advisory Board, Munich, Germany, ³Ruhr-University Bochum, Bochum, Germany, ⁴Rheumatologist, Pirna, Germany, ⁵Epidemiology, German Rheumatism Research Center, Berlin, Germany, ⁶Epidemiology Unit / Rheumatology and Clinical Immunology, German Rheumatism Research Centre (DRFZ) / Charité University Hospital, Berlin, Germany
Background/Purpose: The number of biosimilars approved for the treatment of rheumatoid arthritis (RA) is constantly increasing. Until now, there are just a few analyses investigating…
Abstract Number: 2537 • 2018 ACR/ARHP Annual Meeting
Benefit Study: Results of Interim Analysis of a Pan-European Observational Study to Evaluate Real-World Effectiveness of SB4 Following Transition from Originator Etanercept (ETN) in Patients with Rheumatoid Arthritis (RA) or Axial Spondyloarthritis (AxSpA)
Klaus Krüger¹, Carlo Selmi^2,3, Alain Cantagrel⁴, Miguel A. Abad⁵, Ulrich Freudensprung⁶, Mourad Farouk Rezk⁶ and Janet Addison⁷, ¹Medical Centre of Rheumatology, Munich, Germany, ²Rheumatology and Clinical Immunology Unit, Humanitas Research Hospital, Rozzano (MI), Italy, ³BIOMETRA Department, University of Milan, Milan, Italy, ⁴Center of Rheumatology of CHU, Toulouse, France, ⁵FEA Reumatología, Hospital Virgen del Puerto, Cáceres, Spain, ⁶Biogen International GmbH, Zug, Switzerland, ⁷Biogen Idec, Maidenhead, United Kingdom
Background/Purpose: SB4, a biosimilar to the reference ETN, received EU marketing authorisation in January 2016, based on the totality of evidence from pre-clinical and clinical…
Abstract Number: 289 • 2018 ACR/ARHP Annual Meeting
Adherence of Etanercept in Iraqi Patients with Rheumatoid Arthritis: One- and Five-Year Data from a Local Registry
Nizar Abdulateef Al Ani¹, Faiq Isho Gorial¹, Eman Khedir², Ahmed Hussein², Yasser El Dershaby³ and Ali AlJabban⁴, ¹Baghdad Teaching Hospital, College of Medicine, Baghdad University, Baghdad, Iraq, ²Baghdad Teaching Hospital, Rheumatology Department, Baghdad University, Baghdad, Iraq, ³Pfizer, Dubai, United Arab Emirates, ⁴Pfizer, Baghdad, Iraq
Background/Purpose: Real-world data on adherence to TNFα inhibitors in patients with RA are missing from many regions, including the Middle East. This study evaluated the…
Abstract Number: 548 • 2018 ACR/ARHP Annual Meeting
Persistence in Low Disease Activity or Remission with Etanercept Monotherapy in Patients with Rheumatoid Arthritis: Results from the Corrona Registry
Dimitrios A. Pappas¹, Ying Shan², Tamara Lesperance³, Sabrina Rebello², Elaine Karis⁴, Greg Kricorian⁴, Winnie Hua⁵, Neil A. Accortt⁴ and Scott Stryker⁴, ¹Corrona LLC, Waltham, MA, ²Corrona, LLC, Southborough, MA, ³DOCS Global, Inc., North Wales, PA, ⁴Amgen Inc., Thousand Oaks, CA, ⁵Corrona, LLC, Waltham, MA
Background/Purpose: Monotherapy with etanercept (ETN) may be a viable therapeutic option for maintenance of patients with rheumatoid arthritis (RA) who prefer to eliminate potential burdens…
Abstract Number: 694 • 2018 ACR/ARHP Annual Meeting
Combining Etanercept with Methotrexate Does Not Improve Long Term Sustainability in Patients with Psoriatic Arthritis. Real World Evidence Report from the Quebec Database Rhumadata®
Omar Benryane¹, Louis Coupal² and Denis Choquette², ¹Médecine, Faculté de Médecine de l’Université de Montréal, Montréal, QC, Canada, ²Rheumatology, Institut de Recherche en Rhumatologie de Montréal (IRRM), Montréal, QC, Canada
Background/Purpose: Psoriatic Arthritis (PsA) in a musculoskeletal inflammatory condition associated with psoriasis. It has a heterogeneous set of clinical manifestations which include peripheral arthritis, axial…
Abstract Number: 1009 • 2018 ACR/ARHP Annual Meeting
Monocytes Membrane TNF Expression and Anti-TNF Treatment in Rheumatoid Arthritis
Audrey Paoletti¹, Julien Rohmer², Juliette Pascaud³, Bineta Oumouly¹, Elodie Rivière³, Samuel Bitoun⁴, Gaetane Nocturne² and Xavier Mariette⁵, ¹U1184 IMVA, INSERM U1184, IMVA, Paris Sud University,LabEx LERMIT, le kremlin bicetre, France, ²INSERM U1184, IMVA, Paris Sud University,LabEx LERMIT, Le Kremlin Bicêtre, France, ³Immunology of viral Infections and Autoimmune Diseases, IDMIT, CEA - Université Paris Sud - INSERM U1184, Le Kremlin Bicêtre & Fontenay aux Roses, France, ⁴INSERM U1184, IMVA, Paris Sud University,LabEx LERMIT, le kremlin bicetre, France, ⁵Rheumatology department, Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique- Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, Paris, France
Background/Purpose: Three monocyte subsets have been described based on their CD14 and CD16 expression profiles. The subpopulation CD14+CD16+ being expanded in rheumatoid arthritis (RA) patient.…
Abstract Number: 75 • 2017 ACR/ARHP Annual Meeting
Factors Associated with TNF Receptor 2 Levels Above the Measurable Range in Rheumatoid Arthritis
Michelle Frits¹, Gary Bradwin², Nancy A. Shadick¹, Christine Iannaccone³, Michael Weinblatt¹, Nader Rifai² and Katherine P. Liao⁴, ¹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Laboratory Medicine, Childrens Hospital Boston, Boston, MA, ³Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁴Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Tumor necrosis factor-alpha (TNFa) is involved in the pathogenesis of RA and is increasingly being studied as a biomarker of cardiovascular disease (CVD). While…
Abstract Number: 363 • 2017 ACR/ARHP Annual Meeting
Work Productivity Benefit in Patients with Rheumatoid Arthritis Initiating Etanercept in the United States
Mahdi Gharaibeh¹, Bradley S. Stolshek², Alex Mutebi³, Amy M. Sainski-Nguyen⁴, David Collier⁵ and Emily Durden⁴, ¹Amgen Inc., Thousand Oaks, CA, ²Amgen, Inc., Thousand Oaks, CA, ³Amgen, Thousand Oaks, CA, ⁴Truven Health Analytics, Ann Arbor, MI, ⁵Amgen, Inc, Terni, Italy
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease that can progress to joint destruction, functional impairment and disability that can lead to work productivity…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].